NASDAQ: EVLOEvelo Biosciences Inc Stock
$0.37+0.03 (+8.82%)
Updated Dec 8, 2023
EVLO Price
$0.37
Fair Value Price
$0.62
Market Cap
$7.00M
52 Week Low
$0.30
52 Week High
$40.00
P/E
-0.03x
P/B
-0.26x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$82.35M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.77
Operating Cash Flow
-$74M
Beta
1.11
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EVLO Overview
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EVLO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVLO ($0.37) is undervalued by 40.1% relative to our estimate of its Fair Value price of $0.62 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EVLO ($0.37) is significantly undervalued by 40.1% relative to our estimate of its Fair Value price of $0.62 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
EVLO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EVLO due diligence checks available for Premium users.
Be the first to know about important EVLO news, forecast changes, insider trades & much more!
EVLO News
Valuation
EVLO fair value
Fair Value of EVLO stock based on Discounted Cash Flow (DCF)
Price
$0.37
Fair Value
$0.62
Undervalued by
40.10%
EVLO ($0.37) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EVLO ($0.37) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EVLO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EVLO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.03x
Industry
11.7x
Market
31.32x
EVLO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.26x
Industry
5.42x
EVLO's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.4M
Profit Margin
0%
EVLO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$20.6M
Liabilities
$47.3M
Debt to equity
-1.77
EVLO's short-term liabilities ($39.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVLO's short-term assets ($18.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVLO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EVLO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.4M
Investing
$513.0k
Financing
$19.2M
EVLO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EVLO vs Biotech Stocks
Evelo Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.